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Supplementary Figure 1. Thrombotic microangiopathy is associated with states of elevated type 1 interferon 
in humans (A) Overview of human “hyperinterferon” states (B) Systematic analysis of drug safety literature identifies 
thrombotic microangiopathy as a reported association with every recombinant type 1 interferon subtype currently 
approved for clinical use in Europe. PIL = complication mentioned as a possible association on the Product 
Information Leaflet (C) “Interferonopathic” diseases characterised by elevated “type 1 interferon signatures” in blood 
and affected organs are associated with histopathological evidence of thrombotic microangiopathy in multiple organs. 
  
 
 
 
 
Supplementary Figure 2. Species specificity of interferon signalling is common to all subtypes of type 1 
interferon in clinical use (A) Dendrogram of human interferon subtypes. Recombinant type 1 interferon proteins in 
clinical use highlighted in red. (B) Upregulation of interferon response gene IFIT1 in a mouse immortalised cerebral 
endothelial cell line is observed in response to mouse recombinant interferon-  and , but not human recombinant 
interferon-  and , confirming species specificity of type 1 interferon signalling across major subtypes (* p<0.05 t-test 
compared to no interferon UT= untreated. Error bars denote SEM). Table: Systematic review of publically available 
toxicity reports for human recombinant type 1 interferon therapies identified through FDA. 
 
 
 
  
 
 
Supplementary Figure 3. Spectrum of microvascular abnormalities observed in a focal model of type 1 
interferon toxicity.  
A spectrum of microvascular disease is observed in mice with transgenic production type 1 interferon in the brain. (A-
C) Microvascular pathology in the hippocampus of transgenic mice (black arrow) (D) Dose-dependent microvascular 
pathology was observed across all major brain regions *** p=0.01 one-way ANOVA for each region n=8 each group. 
(E) luminal occlusion with endothelial hyperplasia, Haematoxylin/eosin (F) perivascular inflammatory cell infiltration, 
Haematoxylin/eosin. (G) intravascular calcification (H-J) Haematoxylin/eosin (H+E), CD3 and CD31 
immunohistochemistry shows small blood vessels with T-cell infiltration (CD3) and narrowing of lumen (CD31 
endothelial marker). (K-L) Capillary microaneursyms and dilated small vessels (M) Perivascular infiltration by T-cells 
(CD3, brown). (Scale bars A-D, G, I = 20um, E,F 40um, H 12um) 
 
 
  
 
 
Supplementary Figure 4. Scanning electron microscopy of cerebral microvascular casts. (A-B) Overview of 
technique. Gold-sputtered mounted vascular cast and scanning electron micrograph at low power (x20). (C-F) High 
power electron micrograph of microvascular abnormalities (x350). Abnormal morphology of brain microvasculature 
with variations in microvessel calibre (white arrows), ectatic vessels and microaneurysms (blue arrows) is observed in 
all IFNHigh mice with highest levels of brain-restricted type 1 interferon production (n=6).  
  
  
Supplementary Figure 5. Targeted monitoring for TMA in multiple sclerosis patients treated with high-dose 
interferon-  
From January 2014 – January 2016, following a drug safety alert from the MHRA in December 2013, 3-monthly 
monitoring with full blood count, renal function and blood pressure was introduced as a revised standard of care for 
multiple sclerosis patients treated with high-dose recombinant interferon-1a (>50mcg/week) in major Scottish 
centres. The rationale for monitoring was identification of possible early cases of thrombotic microangiopathy and 
stopping the drug prior to the development of fulminant organ failure.  
(A) Overview of the impact of targeted monitoring of multiple sclerosis patients treated with high interferon- treatment 
(IFN1a>50mcg/week) in Scottish centres. Red figure represents patient presenting to emergency or critical care 
facilities with fulminant IFN TMA and organ failure.  
(B) Since the introduction of targeted monitoring, interferon- was stopped early in two patients who developed new 
severe hypertension with renal dysfunction. These abnormalities resolved fully on cessation of interferon, with no 
subsequent organ damage. (*Severe hypertension  = Clinic systolic blood pressure is 180 mmHg or higher or clinic 
diastolic blood pressure is 110 mmHg or higher, in accordance to UK NICE guidelines. Renal function abnormalities = 
abnormal urea, creatinine or proteinuria). During this monitoring period no cases have presented with fulminant organ 
failure due to interferon-associated thrombotic microangiopathy.  
  
 
Confirmed cases Patient-Years 
Incidence per 
1000 patient-years 
A. Trials 1 1350 0.74 (0.04-3.6) 
B. Retrospective 4 2700 1.48 (0.47-3.6) 
C. Prospective 4 5000 0.8 (0.25- 1.93) 
 
Supplementary Table 1. Estimates of incidence of thrombotic microangiopathy in 3 patient populations 
treated with high-dose interferon-. In all populations efforts have been made to optimise case ascertainment, in 
addition to spontaneous reporting, as detailed below (A) Pooled clinical trials of Rebif New Formulation, the 
formulation used in the UK. (B) Retrospective estimation of incidence of thrombotic microangiopathy in Scotland 2008-
2013. All major multiple sclerosis centres in Scotland have undertaken audit of this period and review of records of 
patients treated with high dose interferon- over this period. (C) Prospective estimation of incidence of thrombotic 
microangiopathy with high dose interferon- across the UK in the year following initial regulatory warning (Dec 2013-
Dec 2014). Number of cases shown are those who have been referred to the national renal thrombotic 
microangiopathy centre with a confirmed diagnosis of interferon--associated thrombotic microangiopathy. Patient-
year estimates for populations B and C were provided by the manufacturer. 
 
  
 Evidence of chronicity 
Chronic 
Changes on 
Renal Biopsy 
Clinical Features 
Prodrome 
≥ 1 month 
Prodrome 
Length/months 
Abnormal 
Parameters 
during 
prodrome 
TMA 1 Yes Yes 4 H, B, R 
TMA 2 Yes Yes 4 H,B 
TMA 3 Yes No 0.2 Not tested 
TMA 4 Yes Yes 6 B 
TMA 5 Yes Yes 3 H,B,R 
TMA 6 Yes Yes 2 Not tested 
TMA 7 N/A Yes 1 Not tested 
TMA 8 Yes Yes 1 Not tested 
 
 
Supplementary Table 2. Pathological and clinical evidence of a chronic pathophysiological process in 
interferon-associated thrombotic microangiopathy. All renal biopsies, where available, displayed evidence of 
chronic changes. Seven out of eight patient describe new and progressive clinical symptoms lasting at least a month. 
When clinical investigations were undertaken during this prodromal period, blood pressure, blood counts and renal 
function tests were abnormal. H = hypertension, B = abnormal blood count, R = abnormal renal function. Clinical 
details of TMA1-5 summarised from Ref 14. TMA6-8 correspond to the new cases described in the main results 
section.  
 
  
Criterion19 
 
Evidence Criteria met? 
Strength of Association Thrombotic microangiopathy is an extremely rare 
spontaneous disease (2.2 per million, Figure 1). The rate 
observed in cohorts treated with high dose interferon (1 per 
1000 patient-years) is consistent with a strong association.  
 
Yes 
Consistency Similar observations of TMA with high dose interferon have 
been made independently in different countries: Canada11, 
France, UK14 
 
 
Yes 
Specificity Other causes of TMA exist. However major environmental 
and genetic confounding factors have been excluded. 
Patients with interferon-TMA have a distinct and consistent 
clinical phenotype. 
 
Yes 
Temporality Interferon treatment precedes the development of TMA. 
 
 
 
 
Yes 
Biologic Gradient Interferon-associated thrombotic microangiopathy is dose-
dependent (Figure 1). 
 
 
 
Yes 
Plausibility/ 
Analogy 
 
 
Drugs are recognised to be strong triggers for TMA. All type 
I interferon therapies in clinical use have been reported to 
cause TMA. 
 
 
Yes 
Experiment A dose-dependent microangiopathy with similar features to 
IFN-TMA can be induced in a focal model of type 1 
interferon toxicity (Figure 2).  
 
 
Yes 
Coherence TMA is associated with other chronic interferon toxicity 
states in humans (Supplementary figure 1). 
 
 
 
Yes 
 
 
 
Supplementary Table 3. The Bradford-Hill criteria for evidence of causation applied to type 1 interferon and 
thrombotic microangiopathy 
 
 
 
  
  
 
Supplementary methods - Clinical 
 
Clinical and genetic analysis by the UK Renal Thrombotic Microangiopathy Centre  
Patients who developed thrombotic microangiopathy were referred to the national thrombotic microangiopathy centre 
in Newcastle for further evaluation and consented to further evaluation including genetic testing. The study was 
approved by Newcastle and North Tyneside 1 Research Ethics Committee (MREC/1/3/83) and informed consent 
obtained in accordance with the Declaration of Helsinki. Patient histories and notes were reviewed for drugs other 
than interferon- which are associated with thrombotic microangiopathy. Whole exome sequencing was performed as 
follows (14): Enrichment from isolated DNA was performed using Agilent SureSelect XT Human All Exon V5 by GATC 
Biotech, Konstanz. Library preparation was performed post-capture, with adaptor sequences and indexing 
incorporated using proprietary methods of GATC Biotech, compatible for Illumina sequencing technology. Illumina 
sequencing was performed on the HiSeq2000 instrument (v3 chemistry).The sequencing reads were analyzed using 
the following workflow to identify variants in patients. The quality of sequencing reads was firstly checked with 
FastQC. Duplicated reads were removed with FastUniq. The remaining reads were mapped to the human reference 
genome GRCb37 with BWA. The alignments were refined with tools of the GATK suite. Variants were called 
according to GATK Best Practice recommendations, including recalibration. Freebayes was also used to call variants 
from the same set of samples. The variants called by Freebayes with total coverage ≥ 5, minor allele coverage ≥ 5 
and variants call quality ≥ 20 were added to those identified by GATK. Non-synonymous exonic variants were 
subsequently filtered by quality and minor-allele frequency (MAF) reported in the 1000 Genomes project (2012 Feb 
release) and ESP6500. Variants with MAF > 0.05 were excluded. Annovar was used for annotations and prediction of 
functional consequences. In addition, duplicate variant annotation and interpretation analyses were generated through 
the use of QIAGEN’s Ingenuity® Variant Analysis™ software (www.qiagen.com/ingenuity) from QIAGEN Redwood 
City. No mutations were found in any genes known to be associated with atypical HUS, as well as genes involved in 
the complement, coagulation and interferon pathways. There was no rare genetic variant (<0.01% frequency in 1000 
genome project) that is present in all patients that is not also present in control panel used at the national UK aHUS 
centre in Newcastle. 
Evaluation of patients with thrombotic microangiopathy associated with a common manufacturing source 
across Scotland 
An audit was registered in NHS Lothian (Department of Clinical Neurosciences Quality Improvement Team 
Registration Number 417) to identify factors contributing to the unexpectedly high number of cases of thrombotic 
microangiopathy associated with interferon-. The audit was triggered by safety concerns regarding the unexpectedly 
high number of cases of thrombotic microangiopathy associated with interferon- in Scottish neuroscience centres. 
The manufacturer and delivery company who provided the interferon were contacted and requests for data were 
submitted with the purpose of identifying the cause for the unexpectedly high number of cases of thrombotic 
microangiopathy as outlined below. Requests for safety data were submitted to the UK and European Drugs regulator 
(MHRA and EMA) and manufacturer as outlined below. Records of patients prescribed high-dose sc interferon-1a 
were reviewed and patients who had developed thrombotic microangiopathy were identified. A similar audit was 
performed in NHS Greater Glasgow and Clyde. Neurologists who prescribe interferon- across Scotland were 
contacted to identify further cases of thrombotic microangiopathy. A drug safety alert issued by the MHRA in Dec 
2013 and subsequent advice advised all doctors to report cases of thrombotic microangiopathy associated with 
interferon- to the MHRA (15, https://www.gov.uk/drug-safety-update/interferon-beta-risk-of-thrombotic-
microangiopathy-and-risk-of-nephrotic-syndrome). The manufacturer provided estimates of the number of patients 
currently receiving treatment with high dose (>50mcg/week) subcutaneous interferon--1a in Scotland and the UK 
(Rebif 22 and Rebif 44, Merck-Serono). Requests were submitted to the European Medicines Agency for all Periodic 
Safety Update Reports and Risk Management Plans related to high dose interferon and thrombotic microangiopathy. 
Patient-year exposure, clinical trial data and incidence data were checked from these documents.  
Safety requests and evaluation of formulation-specific reporting rates 
Requests for spontaneous data to the MHRA were performed as previously described. Dose information was 
available for 12 out of 14 reports, including the new cases described here (14). Twelve cases were associated with a 
common high dose (>50mcg/week) interferon-1a preparation (Rebif, Merck), eleven treated with the highest 
available dose (132 mcg/week). The manufacturer global safety database (Merck) was searched to identify cases of 
HUS/TTP using a custom MedDRA query from 1994 to February 2013, as previously described (14). The identified 
cases included all spontaneously reported, medically confirmed HUS/TTP cases. The patient-year exposure for 
22mcg and 44mcg doses was provided by the manufacturer. Dose information was available for 80% of medically 
confirmed Rebif thrombotic microangiopathy reports. The reporting rate and rate ratios were subsequently determined 
using Stata version 13. 95% confidence intervals were determined according to an exact Poisson method (StataCorp. 
2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP 
http://www.stata.com/support/faqs/resources/citing-software-documentation-faqs/).  
Pooled clinical trial safety data 
Rebif New Formulation is the high-dose formulation currently used in the UK. Therefore the clinical trial database 
(http://www.clinicaltrials.gov/) was searched using the terms “Rebif New Formulation” and “Rebif serum-free 
formulation”. All manufacturer-sponsored clinical trials using RNF at a dose used in clinical practice as monotherapy 
for the treatment of relapsing-remitting multiple sclerosis were identified. The patient-year exposure for patients 
receiving RNF were identified for each trial. Serious adverse reactions of thrombotic microangiopathy or malignant 
forms of hypertension were identified through review of published safety data, with additional safety information 
provided by the manufacturer, confirmed through information requests to the EMA.  
Immunohistochemical analysis 
Where renal biopsies were available, paraffin-embedded renal biopsies from the patients with IFN--associated 
thrombotic microangiopathy were cut into 5 µm sections, rehydrated and boiled in sodium citrate buffer (pH 6.0). 
Sections were stained with mouse-anti-MxA (kind gift, Otto Haller, University of Freiburg; 1:400) followed by staining 
with EnVision™ G|2 System/AP Rabbit/Mouse (Dako) and counterstained with Mayer’s hematoxylin (Merck).  
 
  
Supplementary methods - Experimental 
 
Analysis of cerebral microvasculature in a mouse model of type 1 interferon toxicity 
The generation of transgenic mice with brain-specific production of type 1 interferon (GFAP-IFN1) has been 
previously described(15). Animal experiments were approved by University of Sydney Animal Ethics Committee 
(protocol number 5374). All animal experimental procedures were carried out in compliance with local procedures and 
guidelines. The microvasculature of wildtype mice, transgenic mice with low levels of astrocyte-derived IFN-1 
production (IFN Low, also referred to as GIFN12 line) and high levels of IFN-1 production (IFN High, also referred to as 
GIFN39 line) was examined and quantified. Mice were perfused intracardially at 2-3 months of age, with ice-cold 
saline followed by 4% paraformaldehyde in PBS (n=8, each group). Brains were removed, postfixed overnight in the 
same fixative, dehydrated through graded alcohol solutions, and embedded in paraffin. For immunohistochemical 
detection of T cells and endothelial cells, sections were deparaffinized, rehydrated in graded alcohol, rinsed in 
phosphate-buffered saline (PBS), and blocked for 1 hour at room temperature in PBS containing 1% bovine serum 
albumin. The sections were then incubated overnight at 4°C with primary antibody diluted in blocking buffer (CD3, 
Abcam rabbit monoclonal ab16669 and CD31, Abcam rabbit polyclonal ab28364). The sections were then washed in 
PBS and incubated with anti-rabbit avidin-biotinylated horseradish peroxidase complex (ABC kit; Vector, Burlingame, 
CA) used according to the manufacturer’s instructions. The total number of microvascular abnormalities was counted 
across three X20 magnification fields per anatomical region (cerebellum, cortex, brainstem, thalamus, hippocampus), 
with counting performed blind to mouse genotype. One-way ANOVA was performed across groups for each 
anatomical region and for a mean score across all five regions (GraphPad Prism Version 6.0d).  
Vascular casting of interferon transgenic mice 
Vascular casting of wildtype (n=2) and GIFN39 mice (n=6) was performed as previously described (16), in accordance 
with National Institutes of Health Guidelines for Care and Use of Laboratory Animals. Briefly, deeply anesthetized 
animals were perfused with artificial cerebrospinal fluid (ACSF) containing Heparin, followed by 4% paraformaldehyde 
in PBS, and an injection of the resin Mercox (Ladd Research, Williston, VT). After resin curing, soft tissue was 
subsequently macerated followed by decalcification with 5% formic acid. Casts were washed, then dried by 
lyophilization, mounted on stubs, and sputter-coated with gold for routine scanning electron microscopy. 
RNA isolation and Ribonuclease protection assay.  
Brain was removed and immediately snap-frozen in liquid nitrogen. Total RNA was extracted from the tissue samples 
using TriReagent (Sigma-Aldrich) performed according to the manufacturer’s instructions. The RNA concentration of 
the samples was determined by UV spectroscopy at 260 nm. For all probe sets, a fragment of the L32 gene was 
included and served as an internal loading control. The ribonuclease protection assays (RPAs) for interferon response 
genes were performed and analyzed as described previously (17-18), with autoradiographs quantified by densitometry 
using Image J software, n=3 each group. 
Cell culture, RNA isolation and Quantitative polymerase chain reaction 
BEND.5 mouse brain endothelial cells were plated at 5 x 105 cells per well of a 6 well plate in 1 ml DMEM containing 
10% FCS and incubated at 37°C with 5% CO2. Recombinant mouse or human IFN-α or IFN-β (R+D Systems: Mouse 
interferon alpha A, 12100-1, mouse interferon beta 12400-1, human interferon beta 1a 11415-1, human interferon 
alpha 2 11105-1) was added to culture media at concentrations 0-104U/mL and incubated for 24 hours. Total RNA 
was isolated from each well using QIAshredder and RNeasy (QIAGEN), according to the manufacturer’s instructions. 
Following reverse transcription, 1 µl of cDNA diluted 1:3 was used in each qPCR reaction alongside water controls 
and minus RT controls. Each biological replicate was assayed for expression of OAS1A, IFIT1, and the housekeeping 
gene HPRT using Brilliant II SYBR master mix (Agilent technologies). Thermocycling and data acquisition were 
performed using ABI Prism 7900HT Real-time PCR system. The ΔΔCt method was used to calculate relative gene 
expression. A t-test was performed to compare relative gene expression at highest interferon dose to no interferon. 
(GraphPad Prism Version 6.0d). 
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